
BBIO Stock Forecast & Price Target
BBIO Analyst Ratings
Bulls say
BridgeBio Pharma has demonstrated strong commercial momentum, recording a notable increase in prescriptions for Attruby, with figures rising from 430 to 1,028 patient scripts, and an increase in unique prescribers from 248 to 516 within a short period, signifying robust early-stage demand. This demand is likely bolstered by the favorable mortality data from the phase 3 ATTRibute-CM trial, which has effectively showcased the drug's capabilities in reducing cardiovascular-related hospitalizations and improving patient outcomes. Furthermore, the potential for market expansion through increased awareness and diagnosis, coupled with the positive growth trajectory projected into 2026, supports a favorable long-term outlook for BridgeBio Pharma's stock performance.
Bears say
BridgeBio Pharma faces significant challenges that contribute to a negative outlook, including the lack of robust commercial infrastructure necessary to support the launch of its key product, acoramidis. The company encounters legislative pressures surrounding drug pricing in the U.S. and struggles to form meaningful partnerships or distribution agreements outside the U.S., which limits the potential value of its drug candidates. Furthermore, uncertainties surrounding funding sources and the risk of clinical trial data leading to negative results or delays further exacerbate the potential for medium- to long-term dilution of shareholder value.
This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
BBIO Analyst Forecast & Price Prediction
Start investing in BBIO
Order type
Buy in
Order amount
Est. shares
0 shares